Adv Ther (2018) 35:749–753 https://doi.org/10.1007/s12325-018-0719-8 COMMENTARY To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars Mourad F. Rezk Burkhard Pieper Received: April 16, 2018 / Published online: June 5, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Abstract: In addition to the general clinical clinical trials, and that this effect may nega- beneﬁt offered, biosimilars may not only gen- tively affect acceptance in patients switching erate savings for healthcare budgets but also from an originator product to a biosimilar. improve patient access to biologic products. Awareness of the potential for the nocebo effect Since the ﬁrst biosimilar was approved in Eur- and adoption of enhanced communication ope in 2006, a further 36 different biosimilar techniques may be useful in mitigating the drugs have been approved for several indica- nocebo effect. Effective healthcare profes- tions. Despite the wealth of experience gained sional–patient dialogue is key in transferring and the reported data supporting the use of conﬁdence to the patient, and has been shown biosimilars, both in naı¨ve and biologic-experi- to reduce nocebo effects in patients when enced patients, some healthcare professionals switching from an originator to a biosimilar. continue to express doubt
Advances in Therapy – Springer Journals
Published: Jun 5, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud